A Prospective, Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The specific aim of this protocol is to compare Clozapine treatment vs Non-Clozapine
antipsychotic treatment in a population of treatment-refractory individuals with
schizophrenia. Specifically, it is to test if Clozapine leads to a decrease in levels of
inflammatory markers, namely interleukin-6 but with an exploratory view of other markers.
Clozapine has superior efficacy and is the only medication approved for treatment-refractory
schizophrenia in addition to decreasing the risk of suicidal behavior as well. It is unclear
why Clozapine has increased efficacy from a mechanistic viewpoint. We will look at the role
of inflammatory markers and prospectively track them over the course of 4 months in 4 week
intervals along with rating scales for psychosis and suicidality, the other entities which
Clozapine has been shown to improve.